K. Bélanger

660 total citations
20 papers, 496 citations indexed

About

K. Bélanger is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, K. Bélanger has authored 20 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 9 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in K. Bélanger's work include Glioma Diagnosis and Treatment (9 papers), Cancer Treatment and Pharmacology (5 papers) and Brain Metastases and Treatment (4 papers). K. Bélanger is often cited by papers focused on Glioma Diagnosis and Treatment (9 papers), Cancer Treatment and Pharmacology (5 papers) and Brain Metastases and Treatment (4 papers). K. Bélanger collaborates with scholars based in Canada, United States and New Zealand. K. Bélanger's co-authors include Warren Mason, David R. Macdonald, Peter Forsyth, Thierry Gorlia, Martin J. van den Bent, Roger Stupp, Michael Weller, Charles J. Vecht, Denis Lacombe and J. G. Cairncross and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

K. Bélanger

20 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Bélanger Canada 8 293 195 126 95 85 20 496
Charlotte Abson United Kingdom 8 212 0.7× 139 0.7× 141 1.1× 157 1.7× 20 0.2× 11 500
Shapiro Wr United States 6 330 1.1× 82 0.4× 195 1.5× 84 0.9× 12 0.1× 8 475
Roberta Muni Italy 10 544 1.9× 171 0.9× 342 2.7× 132 1.4× 17 0.2× 11 788
Michael S. Taccone Canada 9 117 0.4× 201 1.0× 28 0.2× 35 0.4× 19 0.2× 18 392
Vinay M. Daryani United States 14 124 0.4× 183 0.9× 128 1.0× 126 1.3× 51 0.6× 16 462
Steve Abella United States 9 133 0.5× 110 0.6× 32 0.3× 68 0.7× 38 0.4× 21 386
Yunyan Wang China 14 53 0.2× 330 1.7× 131 1.0× 72 0.8× 53 0.6× 41 621
P.A. Voûte Netherlands 17 64 0.2× 275 1.4× 94 0.7× 88 0.9× 32 0.4× 40 636
Carl Wibom Sweden 14 184 0.6× 280 1.4× 42 0.3× 54 0.6× 13 0.2× 31 507
Dominique Slaets Belgium 8 58 0.2× 70 0.4× 47 0.4× 79 0.8× 23 0.3× 8 304

Countries citing papers authored by K. Bélanger

Since Specialization
Citations

This map shows the geographic impact of K. Bélanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Bélanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Bélanger more than expected).

Fields of papers citing papers by K. Bélanger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Bélanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Bélanger. The network helps show where K. Bélanger may publish in the future.

Co-authorship network of co-authors of K. Bélanger

This figure shows the co-authorship network connecting the top 25 collaborators of K. Bélanger. A scholar is included among the top collaborators of K. Bélanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Bélanger. K. Bélanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bélanger, K., Nathalie Letarte, Jean‐Philippe Adam, et al.. (2018). Procarbazine, Lomustine and Vincristine Toxicity in Low-Grade Gliomas. Current Oncology. 25(1). 33–39. 16 indexed citations
2.
Bell, Erica H., Minhee Won, Susan M. Chang, et al.. (2017). MGMT Promoter Methylation Status Independently Predicts Overall Survival in Anaplastic Astrocytoma in NRG Oncology/RTOG 9813: A Phase 3 Trial of Radiation Plus Nitrosourea Versus Radiation Plus Temozolomide. International Journal of Radiation Oncology*Biology*Physics. 99(2). S99–S100. 2 indexed citations
3.
Easaw, Jacob C., Warren Mason, James Perry, et al.. (2011). Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme. Current Oncology. 18(3). 126–136. 81 indexed citations
4.
Weller, Michael, Thierry Gorlia, J. G. Cairncross, et al.. (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 77(12). 1156–1164. 210 indexed citations
5.
Mason, Warren, K. Bélanger, Garth Nicholas, et al.. (2010). A phase II trial of TLN-4601 in patients with glioblastoma multiforme (GBM) at first progression.. Journal of Clinical Oncology. 28(15_suppl). 2094–2094. 2 indexed citations
6.
Petrella, Teresa M., Richard Tozer, K. Bélanger, et al.. (2010). Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM).. Journal of Clinical Oncology. 28(15_suppl). 8507–8507. 5 indexed citations
7.
Perry, James, Warren Mason, K. Bélanger, et al.. (2008). The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. Journal of Clinical Oncology. 26(15_suppl). 2010–2010. 21 indexed citations
8.
9.
10.
Gorlia, Thierry, Roger Stupp, E. A. Eisenhauer, et al.. (2004). Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). Journal of Clinical Oncology. 22(14_suppl). 9599–9599. 6 indexed citations
11.
Gorlia, T., Roger Stupp, E. Eisenhauer, et al.. (2004). Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). Journal of Clinical Oncology. 22(14_suppl). 9599–9599. 2 indexed citations
12.
Townsley, Carol, D. Scott Ernst, K. Bélanger, et al.. (2003). Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials Group. Journal of Clinical Oncology. 21(8). 1524–1529. 26 indexed citations
13.
Paz-Ares, L., K. Bélanger, J. Maroun, et al.. (2001). Phase I (PI) trials with aplidine (APL), a new marine derived anticancer compound. European Journal of Cancer. 37. S32–S32. 5 indexed citations
14.
Gertler, S., David Macdonald, Michael Goodyear, et al.. (2000). NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Annals of Oncology. 11(3). 315–318. 30 indexed citations
15.
Bélanger, K., Richard Tozer, Susan Burdette-Radoux, et al.. (1999). Results of a randomized phase II study of two schedules of bryostatin-I in patients with malignant melanoma: experience with the multivariate stopping rule. European Journal of Cancer. 35. S374–S374. 2 indexed citations
16.
Moore, M., et al.. (1999). NCIC CTG IND 103: a Phase I and pharmacokinetic (PK) study of the novel L-nucleoside analog troxacitabine (BCH-4556) given every 21 days. European Journal of Cancer. 35. S284–S284. 4 indexed citations
17.
Blackstein, Martin E., E. Eisenhauer, V. Bramwell, et al.. (1995). 848 Docetaxel (taxotere) as first line therapy for metastatic or recurrent soft tissue sarcoma (STS): A phase II trial. European Journal of Cancer. 31. S177–S177. 5 indexed citations
18.
Jolivet, Jacques, K. Bélanger, Louise Yelle, et al.. (1994). The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. European Journal of Cancer. 30(5). 626–628. 3 indexed citations
19.
Shore, Tsiporah B., Elizabeth A. Eisenhauer, Ian Quirt, et al.. (1993). A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: A study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG). Annals of Oncology. 4(8). 695–696. 3 indexed citations
20.
Speth, P A, et al.. (1988). Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a phase I and clinical pharmacological study.. PubMed. 48(10). 2933–7. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charlotte Abson Breakdown of academic impact, for papers by Shapiro Wr Breakdown of academic impact, for papers by Roberta Muni Breakdown of academic impact, for papers by Michael S. Taccone Breakdown of academic impact, for papers by Vinay M. Daryani Breakdown of academic impact, for papers by Steve Abella Breakdown of academic impact, for papers by Yunyan Wang Breakdown of academic impact, for papers by P.A. Voûte Breakdown of academic impact, for papers by Carl Wibom Breakdown of academic impact, for papers by Dominique Slaets
Rankless by CCL
2026